FRIDAY, Sept. 12, 2025 (HealthDay News) -- The U.S. Food and Drug Administration is taking new steps to regulate direct-to-consumer drug advertisements and eliminate misleading advertisements out of ...

On September 9, 2025, the U.S. Food and Drug Administration (FDA) and Department of Health and Human Services (HHS) dropped a regulatory bombshell: the FDA issued approximately 100 cease-and-desist ...

Additionally, the agency is eliminating the 'adequate provision' loophole that allowed pharmaceutical companies to list complete risks separately. (HealthDay News) — The U.S. Food and Drug ...

The FDA has also initiated rulemaking to eliminate the 1997 "adequate provision" loophole, which allowed companies to include a "major-risk statement" and then direct viewers to a website, toll-free ...

Please provide your email address to receive an email when new articles are posted on . The FDA said it will send letters to pharmaceutical companies asking for the removal of “misleading” drug ads.

Those ever-present TV drug ads showing patients hiking, biking or enjoying a day at the beach could soon have a different look: New rules require drugmakers to be clearer and more direct when ...

Rulemaking to remove its longstanding “adequate provision” framework, described as a “loophole” undermining “informed patient consent” that has allegedly enabled companies to “hide safety information.

The U.S. Department of Health and Human Services and the Food and Drug Administration announced major reform on Tuesday that requires pharmaceutical companies to include full safety warnings in direct ...

President Donald Trump on Tuesday signed a memorandum that aims to crack down on direct-to-consumer prescription drug ads. The U.S. Department of Health and Human Services and the Food and Drug ...

WASHINGTON — For the first time, federal health officials are taking aim at telehealth companies promoting unofficial versions of prescription drugs — including popular weight loss medications — as ...

The Trump administration’s crackdown on pharmaceutical ads is a welcome step toward lessening Big Pharma’s influence over conversations between patients and their doctors. Americans are among the few ...